Sign in
RNXT Stock Price, Chart, Stats & News
RenovoRx, Inc.
Save
34.25M
Market cap
–
Current P/E
–
Forward P/E
RNXT chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 67.78% |
Operating margin | -1252.16% |
Pretax margin | -1196.66% |
Net margin | -1196.66% |
Effective tax rate | – |
ROA | -99.10% |
ROE | -122.19% |
D/E | 0.03x |
Interest coverage ratio | – |
RNXT valuation
P/E | – |
P/S | 44.63x |
P/B | 5.13x |
P/CF | -3.99x |
P/FCF | -3.98x |
P/OCF | -3.99x |
PEG | -0.73x |
EV multiple | -6.40x |
About
RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies. The company's primary investigational therapy, RenovoGem, is an innovative drug and device combination. It integrates intra-arterial gemcitabine with the RenovoCath system, currently progressing through pivotal Phase III clinical trials for the treatment of locally advanced pancreatic cancer.
Similar securities
Based on sector and market capitalization
Report issue